New pill aims to tame CAR t-cell side effects in lymphoma patients
Disease control
Recruiting now
This study tests a new drug called CTO1681 to prevent or reduce cytokine release syndrome (CRS), a serious immune overreaction, in adults with diffuse large B-cell lymphoma who are receiving CAR T-cell therapy. About 54 participants will take CTO1681 three times daily for 15 days…
Phase: PHASE1, PHASE2 • Sponsor: CytoAgents, Inc. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC